Moberg Pharma’s nomination committee appointed

STOCKHOLM, November 8th, 2018 – In accordance with the resolution of the Annual General Meeting on May 15th, 2018, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the fourth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 15th, 2018.

Moberg Pharma’s Nomination Committee ahead of the 2019 Annual General Meeting comprises:

  •  Thomas Eklund, Chairman of the Board
  •  Gillis Cullin, appointed by Östersjöstiftelsen
  •  Fredrik Persson, appointed by Zimbrine Holding
  •  Anders Lundmark

Together, the Nomination Committee represents 25.27 percent of the shares in Moberg Pharma as of September 28th, 2018.

The Nomination Committee shall submit proposals for resolution by the 2019 Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors’ fees and the election of auditors.

The 2019 Annual General Meeting will be held in Stockholm on May 15th.

Shareholders wishing to submit proposals to Moberg Pharma’s Nomination Committee can do so by e-mail to info@mobergpharma.se by 31 December 2018.

About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 8.30 a.m. CET on November 8th, 2018.

For additional information, please contact:
Peter Wolpert, CEO, Phone: +46 707 35 71 35 (SE), e-mail: peter.wolpert@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 30 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, New Skin®, Dermoplast®and Domeboro®. Kerasal Nail®(Emtrix®, Zanmira®or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

Tags:

About Us

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, for which phase 3 data in more than 800 patients is expected in late 2019 in North America and the first half of 2020 in Europe. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

Contacts